NCT06451211View on ClinicalTrials.gov

Neoadjuvant Immunotherapy Plus Chemotherapy in Borrmann Type 4 and Large Type 3 Gastric Cancer

PHASE2RecruitingINTERVENTIONAL
Enrollment

53

Participants

Timeline

Start Date

May 17, 2023

Primary Completion Date

November 30, 2024

Study Completion Date

November 30, 2027

Conditions
Stomach NeoplasmsGastric CancerLinitis Plastica of Stomach
Interventions
DRUG

Tislelizumab

Tislelizumab 200 mg will be administered systemically on day 1 of each cycle in all participants

DRUG

Oxaliplatin

Oxaliplatin 150 mg will be administered systemically on day 1 of each cycle in all participants

DRUG

S-1

S-1 40 mg will be administered orally on day 1-14 of each cycle in all participants

DRUG

Capecitabine

Capecitabine 2500 mg will be administered orally on day 1-14 of each cycle in all participants

Trial Locations (1)

510010

RECRUITING

Sun Yat-sen University Cancer Center, Guangzhou

All Listed Sponsors
lead

Sun Yat-sen University

OTHER